CDC green-lights GSK's meningitis vaccine for at-risk infants

A Centers for Disease Control and Prevention panel recommended the use of GlaxoSmithKline's ($GSK) MenHibrix vaccine for bacterial meningitis for use in babies at increased risk of infection. The vaccine can also be used in babies aged 2 months through 18 months who live in communities battling outbreaks of meningococcal disease caused by serogroups C and Y, Reuters reports. The decision is unrelated to an outbreak of fungal meningitis that has been linked to tainted steroid injections and has so far killed 24 people. Story

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.